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Abstract
Background: Suitable biomarkers associated with the development of delirium are still not known. Urinary
proteomics has successfully been applied to identify novel biomarkers associated with various disease states, but its
value has not been investigated in delirium patients.
Results: In a prospective explorative study hyperactive delirium patients after cardiac surgery were included for
urinary proteomic analyses. Delirium patients were matched with non-delirium patients after cardiac surgery on
age, gender, severity of illness score, LOS-ICU, Euro-score, C-reactive protein, renal function and aorta clamping
time. Urine was collected within 24 hours after the onset of delirium. Matrix-assisted laser desorption/ionisation-
time of flight mass spectrometry (MALDI-TOF MS) was applied to detect differences in the urinary proteome
associated with delirium in these ICU patients. We included 10 hyperactive delirium and 10 meticulously matched
non-delirium post-cardiac surgery patients. No relevant differences in the urinary excretion of proteins could be
observed.
Conclusions: We conclude that MALDI-TOF MS of urine does not reveal a clear hyperactive delirium proteome
fingerprint in ICU patients.
Trial Registration: Clinical Trial Register number: NCT00604773
Background
Delirium is an acute psycho-organic syndrome, that fre-
quently occurs in hospitalized patients and particularly
in critically ill patients. This neuropsychiatric disorder is
associated with serious health problems, such as pro-
longed stay on the mechanical ventilator, in the inten-
sive care unit (ICU) and hospital, and a higher mortality
rates [1]. Three subtypes of delirium; hyperactive,
hypoactive and a mixed subtype, can be distinguished
based on patients Richmond Agitation Sedation Scores
(RASS) [2]. In daily practice, nurses and physicians
experience the most difficulties with the hyperactive
delirium patients who are often aggressive or even com-
bative and in whom their delirium is associated with
dislocation of their endotracheal tube and other lifesav-
ing materials.
Although the pathophysiology of delirium is far from
clear, several biomarkers and pathways, such as neuro-
anatomic abnormalities, cholinergic failure, inflammatory
responses and activation of the hypothalamic-pituitary
adrenal axis, were found to be associated with the devel-
opment of delirium [3;4]. Nevertheless, suitable biomar-
kers that may facilitate the diagnosis of delirium have not
been discovered.
Proteomics is a profiling method to detect a wide
range of markers simultaneously. This technique allows
the identification of several proteins potentially involved
in the pathophysiological mechanism of disorders [5],
such as delirium. Proteomics can be applied for determi-
nations in tissue [6] and in several biological fluids, i.e.
cerebro-spinal fluid and serum [7-9]. Differences in pro-
tein profiles were detected in brain tissue of hyperactive
delirium rats (significant peak at m/z 5030 and 5179)
[10] and in the serum of delirium elderly patients with
hip fracture (significant peak at m/z 15,900 identified as
haemoglobin-b) [8]. Proteomics of urine samples is of
special interest, as urine reflects the low molecular
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weight protein pool of blood without, for mass spectro-
metry disturbing, abundant proteins, such as albumin
[11]. In addition, urine can be collected in a non-invasive
way. Proteomics of urine has proven to be useful in
predominantly urogenital diseases, but has recently also
been implicated in non-urogenital diseases including
cancer and coronary artery disease [12;13]. In addition,
the detection of differential protein expression in delir-
ium patients may facilitate the understanding of the
pathophysiology of disease.
The aim of our present study was to explore whether
biomarkers associated with delirium could be detected
in urinary protein profiles of hyperactive delirium com-
pared to matched non-delirium ICU- patients.
Methods
Patients and delirium assessment
For this explorative study 10 hyperactive delirium post
cardiac surgery patients were included and compared
with 10 meticulously matched non-delirium patients.
For sake of homogeneity, delirium patients after cardiac
surgery were included only when they suffered from a
hyperactive delirium [2], detected with the validated
Dutch version of the confusion assessment method-ICU
[14] by well trained ICU nurses [15]. Patients were diag-
nosed, according to the Peterson criteria [2], as hyperac-
tive delirium when they had only positive RASS during
their delirium period. Patients were double checked by a
delirium expert (MvdB) for the presence or absence of
the delirium to confirm the diagnosis. To secure that
only hyperactive delirium patients were included, fol-
low-up took place until patients did not suffer from
delirium anymore and only when they had positive
RASS scores during their delirium period. In support of
the homogeneity of the total group, patients were
matched on several important risk factors for the devel-
opment of delirium [16]. Matching was performed on:
gender, age, length of stay on the ICU at the time of
urine sample collection, severity of illness score
(expressed in Acute Physiology and Chronic Health Eva-
luation (APACHE)-II score), C-reactive protein (CRP),
Aorta clamping time, Euro score, serum and urine crea-
tinine level, modification of diet in renal disease - glo-
merular filtration rate (MDRD-GFR) and type of
operation. Patients suffering from an infection were
excluded.
The local Institutional Review Board of Arnhem-
Nijmegen (study number 2007/283) indicated that for
this study no formal approval was required and no
informed consent from patients was needed because of
the observational nature of this study and the fact that no
additional interventions were carried out. This study was
registered on Clinical Trial Register as NCT00604773.
Sample collection, preparation and measurement
Within 24 hours after the onset of the delirium episode
blood and urine were collected for creatinine measure-
ment and urine for proteomics profiling under sterile
conditions. As a control, a urine master pool was cre-
ated according to Vanhoutte et al [13], which consisted
of urine of 24 healthy volunteers (age 22-65 years). In
brief, first-morning mid-stream urine samples were col-
lected freshly and a master pool reference sample of all
healthy volunteers was prepared by mixing together 24
urine samples containing 0.2 mmol creatinine each. Pro-
tease inhibitors were added to the urine immediately
after the collection and the samples were centrifuged
(15 min, 2000g at 4°C) and stored in small aliquots at
-80°C to minimize freeze-thaw cycles.
MALDI-TOF-MS analysis: preparation and measurement
To isolate proteins from the urine samples we used
magnetic bead (MB) separation [17] with magnetic
hydrophobic-interaction chromatography (MB-HIC C8),
immobilized metal ion affinity chromatography (MB
IMAC-Cu) and weak cation-exchange chromatography
(MB WCX) beads. In addition, non-magnetic weak
cation-exchange beads (CM10, Bruker Daltronics,
Germany) were applied. Urine volume added to the
beads was normalized to urine creatinine concentration.
A urine volume of maximally 30 μL was used for
MB-HIC C8 and HB IMAC-Cu; 15 μL for MB-WCX
and 150 μL for CM10 beads. To all samples an internal
standard of 5 μL 0.5mM hepcidin 24 was added to
normalize peak intensities [18]. MB purifications were
performed according to the manufacturer’s protocol for
serum using the buffers delivered with the kit. For
MB-WCX and CM10 beads other buffers were used as
described by Kroot [19], based on Park [20]. Pre-treated
samples were transferred to a polished steel plate
(Bruker Daltronics) and covered with two layers of
5 mg/mL a-cyano-4-hydroxy-cinnamic acid matrix
(CHCA; Bruker Daltronics). A linear matrix-associated
laser desorption/ionization time-of-flight mass spectro-
meter (MALDI-TOF MS Microflex, Bruker Daltronics)
was used for protein profiling.
Statistics
Since the exploratory nature of this study, a power cal-
culation for sample size calculation was not performed.
Group differences were tested two-tailed using the
Mann-Whitney U-test. Mass spectra data obtained after
MALDI-TOF MS profiling were analyzed using ClinProt
Tools Software (Bruker Daltronics), including univariate
statistical analysis and unsupervised hierarchic cluster-
ing. A two tailed P-value of < 0.05 was considered statis-
tically significant.
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Results
The delirium and non-delirium post-cardiac surgery
ICU patients were comparable regarding the matched
variables (Table 1). The significantly higher RASS score
in the delirium group is a result of the hyperactive delir-
ious state of these patients compared with non-delirium
patients. All patients were mechanically ventilated at the
time of ICU admission, however, none of the patients
was ventilated during the study period. Included patients
did not receive any sedatives and all patients were trea-
ted with morphine according to our postoperative pro-
tocol. All blood and urine was collected in the morning,
except for two patients (one in each group) in whom
urine was collected in the afternoon.
Figure 1 shows representative examples of protein
spectra of our master pool urine, which served as a con-
trol reference sample, a non-delirium patient and a
delirium patient. After unsupervised hierarchic cluster-
ing, the urine protein profiles of all ICU patients dif-
fered from the master pool urine protein profiles,
however, a clear distinction between delirium and non-
delirium patients could not be made. Urine proteomics
profiling did not reveal protein patterns discriminative
for delirium within the ICU patients. However, we
found two protein masses to be more abundantly
expressed in the non-delirium ICU patients compared
to the delirium patients as assessed by the ClinProTools.
The clinical relevance of the 11735.7 Da (p < 0.044)
mass and its suspected double charged form of 5867.12
Da (p < 0.044) in urine samples of non-delirium ICU
patients is, however, questionable since these masses
were found in both types of ICU patients and were
highly variable. The mean mass intensity and standard
deviation of 11735.7 Da in the urine of delirium ICU
patients was 22.12 ± 23.47 compared to 32.1 ± 22.1 for
the non-delirium ICU patients. For the 5867.12 Da mass
this was 12.3 ± 12.3 versus 17.7 ± 10.7, respectively.
Efforts to identify these protein masses were not under-
taken because of the poor discriminative properties (viz.
borderline statistical difference) in delirium ICU
patients.
Discussion
This study shows no relevant differences in urine pro-
tein profiles between hyperactive delirium and matched
non-delirium post cardiac surgical ICU patients. We
could not reproduce the findings from previous studies
that reported protein pattern specific for delirium in
serum, including haemoglobin-b [8], S100-b [21;22] or
other unidentified peaks at m/z 5030 and 5179 in rats
withdrawn from cocaine exposure [10]. This could indi-
cate that no clear hyperactive delirium protein finger-
print is present in the urine of ICU patients or that
associated proteins present in brain or serum do not
pass the blood-brain-barrier or are not excreted in
urine. Although mass spectrometry can be accurately
applied to detect proteins over a very wide range with
good sensitivity, there are some limitations to biomarker
detection using proteomic protein profiling. In this
study, beads were used to isolate proteins from urine
and to eliminate disturbing salts for MALDI-TOF MS
analysis. Disadvantages of this method are that proteins
Table 1 Demographic, matched and outcome variables of delirium and non-delirium patients
Delirium group
(N = 10)
Non-delirium group
(N = 10)
p-value
Admission time (days) 1 [1-1.5] 1 [1] 0.91
Gender (Male) 7 6 0.65
Age (years) 75 [70-78] 75 [68-78] 0.73
RASS-score (median) 0 [0 - 1] -0.5 [-1 - 0] 0.007
APACHE-II score 17 [14-19] 17 [13-21] 0.88
C-reactive protein 41 [35-58] 38 [13-48] 0.28
Aorta clamping time (minutes) 79 [63-94] 106 [66-115] 0.35
Euro score 7 [6-9] 7 [6-12] 0.70
Measurement Creatinine after operation in hours 21 [14-43] 21 [15-21] 0.78
Serum Creatinine μmol/L 97 [86-114] 86 [57-125] 0.32
Urine Creatinine μmol/L 11 [7-6] 8 [6-12] 0.25
MDRD-GFR (ml/min/1.73m2) 69 [55-75] 71 [52-102] 0.45
Type of operation CABG N = 4 CABG N = 3 0.87
Valve operation N = 2 Valve operation N = 1
Valve/CABG N = 2 Valve/CABG N = 3
Miscellaneous N = 2 Miscellaneous N = 3
All values are median [interquartile range 25-75%] unless other reported.
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may be lost due to competition for binding to the beads
and the use of beads may lead to protein selection. In
addition, matrix based ionization is susceptible to signal
suppression [23]. Other mass spectrometry methods
based on electrospray ionization, such as LC-MS/MS
are less susceptible to signal suppression and have a
higher sensitivity, but are also more sensitive to interfer-
ing compounds such as lipids and detergents. Moreover,
LC-MS/MS is time consuming and not suitable for
high-throughput screening.
Figure 1 Protein spectra and hierarchical cluster after profiling with CM10 beads. A. Protein spectra of masterpool urine (upper panel), a
non-delirium patient (middle panel) and a delirium patient (lower panel). The x-axis depicts m/z values in Dalton; the y-axis shows the relative
peak intensity. B. Unsupervised hierarchical clustering determines whether patient groups can be differentiated solely based on their urine
protein profile. On the right hand side the samples are represented. The lengths of the horizontal lines represent the resemblance of the spectra;
the shortest lines represent the most alikeness between samples. In this hierarchic cluster our masterpool can be clearly distinguished from the
ICU patients, but there is no distinction between delirium and non-delirium patients.
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To identify a biomarker pattern specific for a pathologi-
cal condition it is essential to have homogeneous patients
groups. Intra-group variability and the relatively small
sample size may have hindered to discover differences
between the patient groups. To limit this variability, kid-
ney function and aorta clamping time [24] were meticu-
lously matched between the studied groups. Still, ICU
patients have a higher urine protein content as compared
to healthy controls (mean 0.22 ± SD 0.13 g/L compared to
< 0.100 ± 0.002g/L in masterpool control urine samples),
Challenging the discovery of a discriminative protein in
these ICU patients a challenge. In addition, the sample
size of our study was relatively small, therefore there is a
possibility of a type-II error. However, we did not find any
clear protein profile difference between delirium and non-
delirium patients, which could be an indication of a speci-
fic delirium protein in the urine. Consequently we believe
that the possibility of a false negative finding is very low.
Conclusion
No relevant differences in urine protein profiles between
hyperactive delirium and matched non-delirium post
cardiac surgical ICU was found. MALDI-TOF MS did
not reveal a specific hyperactive delirium protein finger-
print in ICU patients.
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